Xuewei Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuewei Bai has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Bei Sun
Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
4 shared publications Bei Sun
Key Laboratory of Hepatosplenic Surgery, Ministry of Education, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China
3 shared publications- Hongze Chen
Department of Hepatobiliary and Pancreas Surgery, The First Affiliated Hospital of Harbin Medical University
3 shared publications Zu-Chao Du
Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
3 shared publicationsJiaming Li
The Pancreatic Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Harbin Medical University, Harbin, China
2 shared publicationsKai-Song Bai
Department of Hepatobiliary and Pancreatic Surgery, Qunli Branch, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 921
Robot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study
- 31 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 921
Open AccessRobot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study
- Open Access
RBX1+ CAFs Drives Pancreatic Ductal Adenocarcinoma Progression Through Tenascin C Overexpression
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that actively drives malignant progression. However, the specific contributions of E3 ubiquitin ligases within the cancer-associated fibroblast (CAFs) compartment to the PDAC landscape remain largely elusive. Methods: Pancreatic tissue samples were collected from the First Affiliated Hospital of Harbin Medical University. Gene expression was analyzed by RT-PCR, and single-cell RNA sequencing (scRNA-seq) data were integrated for cell subtype identification. Kaplan-Meier survival analysis assessed gene expression and survival. Pseudotime analysis and CellChat evaluated fibroblast transitions and intercellular communication. Cell lines were transfected with RBX1 siRNAs, and protein levels were measured by Western blotting. Proliferation was assessed using colony formation and EdU staining. Statistical analyses were performed using R (v4.4) and GraphPad Prism 8.0. Results: Thirteen E3 ubiquitin ligases were significantly upregulated in PDAC and correlated with unfavorable clinical outcomes. Among these, RBX1 was identified as a candidate preferentially expressed in CAF populations and strongly associated with poor prognosis. Single-cell transcriptomic profiling and pseudotime analysis further revealed that RBX1-positive CAFs were predominantly involved in extracellular matrix remodeling and pro-tumorigenic pathways. Functional assays demonstrated that silencing RBX1 markedly inhibited PAAD cell proliferation and tumor growth both in vitro and in xenograft models. Mechanistically, RBX1 was found to upregulate Tenascin C (TNC) expression, while ectopic overexpression of TNC partially rescued the growth suppression induced by RBX1 knockdown. Conclusions: Our findings suggest that RBX1 facilitates PDAC progression through a CAF-related mechanism and TNC regulation, positioning RBX1 as a potential therapeutic target for PDAC intervention.
Open AccessRBX1+ CAFs Drives Pancreatic Ductal Adenocarcinoma Progression Through Tenascin C Overexpression
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that actively drives malignant progression. However, the specific contributions of E3 ubiquitin ligases within the cancer-associated fibroblast (CAFs) compartment to the PDAC landscape remain largely elusive. Methods: Pancreatic tissue samples were collected from the First Affiliated Hospital of Harbin Medical University. Gene expression was analyzed by RT-PCR, and single-cell RNA sequencing (scRNA-seq) data were integrated for cell subtype identification. Kaplan-Meier survival analysis assessed gene expression and survival. Pseudotime analysis and CellChat evaluated fibroblast transitions and intercellular communication. Cell lines were transfected with RBX1 siRNAs, and protein levels were measured by Western blotting. Proliferation was assessed using colony formation and EdU staining. Statistical analyses were performed using R (v4.4) and GraphPad Prism 8.0. Results: Thirteen E3 ubiquitin ligases were significantly upregulated in PDAC and correlated with unfavorable clinical outcomes. Among these, RBX1 was identified as a candidate preferentially expressed in CAF populations and strongly associated with poor prognosis. Single-cell transcriptomic profiling and pseudotime analysis further revealed that RBX1-positive CAFs were predominantly involved in extracellular matrix remodeling and pro-tumorigenic pathways. Functional assays demonstrated that silencing RBX1 markedly inhibited PAAD cell proliferation and tumor growth both in vitro and in xenograft models. Mechanistically, RBX1 was found to upregulate Tenascin C (TNC) expression, while ectopic overexpression of TNC partially rescued the growth suppression induced by RBX1 knockdown. Conclusions: Our findings suggest that RBX1 facilitates PDAC progression through a CAF-related mechanism and TNC regulation, positioning RBX1 as a potential therapeutic target for PDAC intervention.
- Open Access
- 25 November 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (1) , 26-41
RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement
Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.
- 25 November 2025
- Published by Springer Nature in Oncogene
- Vol. 45 (1) , 26-41
Open AccessRNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement
Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.
- Open Access
- 16 June 2023
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 7 (1) , 61-71
The role of gut microbiota in acute pancreatitis: new perspectives in pathogenesis and therapeutic approaches
Acute pancreatitis (AP) is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden. Gut microbiota disturbance, mucosal barrier failure, and bacterial translocation are identified as the dominant cause of infected pancreatic necrosis and high mortality. With the advance of high-throughput sequencing, imbalance between beneficial and facultative pathogenic microorganisms with their metabolic activities in the development of AP has been increasingly recognized, whereas it remains unclear whether dysbacteriosis is the dominant cause of aggravating AP, or merely reflecting different epidemiological or environmental factors at the individual level. This review discussed the alterations of the gut microbiota and their metabolites during AP with detailed molecular mechanisms. Importantly, it highlights microbiome-based medical therapies which influence gut barrier function and immune homeostasis to mitigate inflammatory responses in AP. Our review will provide a novel roadmap of gastrointestinal microecology in AP progression, and contribute to the future development of microbiome-based diagnostic and therapeutic strategies in clinical practice.
- 16 June 2023
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 7 (1) , 61-71
Open AccessThe role of gut microbiota in acute pancreatitis: new perspectives in pathogenesis and therapeutic approaches
Acute pancreatitis (AP) is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden. Gut microbiota disturbance, mucosal barrier failure, and bacterial translocation are identified as the dominant cause of infected pancreatic necrosis and high mortality. With the advance of high-throughput sequencing, imbalance between beneficial and facultative pathogenic microorganisms with their metabolic activities in the development of AP has been increasingly recognized, whereas it remains unclear whether dysbacteriosis is the dominant cause of aggravating AP, or merely reflecting different epidemiological or environmental factors at the individual level. This review discussed the alterations of the gut microbiota and their metabolites during AP with detailed molecular mechanisms. Importantly, it highlights microbiome-based medical therapies which influence gut barrier function and immune homeostasis to mitigate inflammatory responses in AP. Our review will provide a novel roadmap of gastrointestinal microecology in AP progression, and contribute to the future development of microbiome-based diagnostic and therapeutic strategies in clinical practice.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 15
Impact of COVID-19 pandemic on acute pancreatitis presentations, management, and in-hospital outcomes: a single-center, retrospective observational study from the northeast of China
Background: Since initially detected in late December 2019, the novel coronavirus disease 2019 (COVID-19) outbreak rapidly swept the world, which has profoundly affected healthcare system and clinical practice in the management of gastrointestinal diseases. Objectives: We aimed to evaluate the impact of COVID-19 pandemic on the pattern of hospital admissions and healthcare services for acute pancreatitis (AP). Design: We conducted a retrospective observational cohort study using the anonymized electronic medical records. Methods: This single-center, retrospective observational study from a regional medical center in the northeast of China included all consecutively admitted patients with AP from 23 January to 10 June 2020 (during the COVID-19 outbreak in Harbin), compared with the equivalent period of the previous year, in terms of demographics, clinical characteristics, and in-hospital outcomes. Results: In this article, we observed a reduction in AP admissions after the beginning of COVID-19 outbreak. With the prolonged time from symptom onset to hospitalization [32.0 (22.0–72.0) versus 18.0 (12.0–24.0) h; p < 0.001], a higher proportion of AP patients developed acute renal failure (14.0% versus 7.4%, p = 0.004) and acute necrotic collection (16.5% versus 11.2%; p = 0.038) in the COVID-19 era. The percentage of alcohol etiology significantly decreased after the implementation of social restriction measures (11.5% versus 20.4%; p = 0.002), whereas biliary etiology was numerically more common amidst the COVID-19 era (41.6% versus 32.6%; p = 0.014). No significant differences were found in the rates of intensive care unit admission and mortality between the two groups. Conclusion: This study preliminarily demonstrated the descending trend and delay in hospital presentations for AP during the outbreak of COVID-19. Given that the pandemic may persist for several years, adjustments of medical services according to the varying degrees of local breakouts are imperative to provide appropriate care for AP patients and diminish the risk of viral transmission. Registration: ClincialTrials.gov number ChiCTR2100043350.
- 1 January 2022
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 15
Open AccessImpact of COVID-19 pandemic on acute pancreatitis presentations, management, and in-hospital outcomes: a single-center, retrospective observational study from the northeast of China
Background: Since initially detected in late December 2019, the novel coronavirus disease 2019 (COVID-19) outbreak rapidly swept the world, which has profoundly affected healthcare system and clinical practice in the management of gastrointestinal diseases. Objectives: We aimed to evaluate the impact of COVID-19 pandemic on the pattern of hospital admissions and healthcare services for acute pancreatitis (AP). Design: We conducted a retrospective observational cohort study using the anonymized electronic medical records. Methods: This single-center, retrospective observational study from a regional medical center in the northeast of China included all consecutively admitted patients with AP from 23 January to 10 June 2020 (during the COVID-19 outbreak in Harbin), compared with the equivalent period of the previous year, in terms of demographics, clinical characteristics, and in-hospital outcomes. Results: In this article, we observed a reduction in AP admissions after the beginning of COVID-19 outbreak. With the prolonged time from symptom onset to hospitalization [32.0 (22.0–72.0) versus 18.0 (12.0–24.0) h; p < 0.001], a higher proportion of AP patients developed acute renal failure (14.0% versus 7.4%, p = 0.004) and acute necrotic collection (16.5% versus 11.2%; p = 0.038) in the COVID-19 era. The percentage of alcohol etiology significantly decreased after the implementation of social restriction measures (11.5% versus 20.4%; p = 0.002), whereas biliary etiology was numerically more common amidst the COVID-19 era (41.6% versus 32.6%; p = 0.014). No significant differences were found in the rates of intensive care unit admission and mortality between the two groups. Conclusion: This study preliminarily demonstrated the descending trend and delay in hospital presentations for AP during the outbreak of COVID-19. Given that the pandemic may persist for several years, adjustments of medical services according to the varying degrees of local breakouts are imperative to provide appropriate care for AP patients and diminish the risk of viral transmission. Registration: ClincialTrials.gov number ChiCTR2100043350.
- Open Access
- 25 October 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-11
Lnc-PFAR facilitates autophagy and exacerbates pancreatic fibrosis by reducing pre-miR-141 maturation in chronic pancreatitis
Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.
- 25 October 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-11
Open AccessLnc-PFAR facilitates autophagy and exacerbates pancreatic fibrosis by reducing pre-miR-141 maturation in chronic pancreatitis
Chronic pancreatitis (CP) is described as progressive inflammatory fibrosis of pancreas, accompanied with irreversible impaired endocrine and exocrine insufficiency. Pancreatic stellate cells (PSCs) are widely distributed in the stroma of the pancreas and PSCs activation has been shown as one of the leading causes for pancreatic fibrosis. Our previous study has revealed that autophagy is dramatically activated in CP tissues, which facilitates PSCs activation and pancreatic fibrosis. Long non-coding RNAs (LncRNAs) have been recognized as crucial regulators for fibrosis-related diseases. LncRNAs interact with RNA binding protein or construct competitive endogenous RNA (ceRNA) hypothesis which elicited the fibrotic processes. Until now, the effects of lncRNAs on PSCs activation and pancreatic fibrosis have not been clearly explored. In this study, a novel lncRNA named Lnc-PFAR was found highly expressed in mouse and human CP tissues. Our data revealed that Lnc-PFAR facilitates PSCs activation and pancreatic fibrosis via RB1CC1-induced autophagy. Lnc-PFAR reduces miR-141 expression by suppressing pre-miR-141 maturation, which eventually upregulates the RB1CC1 and fibrosis-related indicators expression. Meanwhile, Lnc-PFAR enhanced PSCs activation and pancreatic fibrosis through trigging autophagy. Our study interrogates a novel lncRNA-induced mechanism in promoting the development of pancreatic fibrosis, and Lnc-PFAR is suggested to be a prospective therapeutic target in clinical scenarios.
- Open Access
- 9 September 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) is one of the deadliest malignancies and mortality for PAAD have remained increasing under the conditions of substantial improvements in mortality for other major cancers. Although multiple of studies exists on PAAD, few studies have dissected the oncogenic mechanisms of PAAD based on genomic variation. In this study, we integrated somatic mutation data and gene expression profiles obtained by high-throughput sequencing to characterize the pathogenesis of PAAD. The mutation profile containing 182 samples with 25,470 somatic mutations was obtained from The Cancer Genome Atlas (TCGA). The mutation landscape was generated and somatic mutations in PAAD were found to have preference for mutation location. The combination of mutation matrix and gene expression profiles identified 31 driver genes that were closely associated with tumor cell invasion and apoptosis. Co-expression networks were constructed based on 461 genes significantly associated with driver genes and the hub gene FAM133A in the network was identified to be associated with tumor metastasis. Further, the cascade relationship of somatic mutation-Long non-coding RNA (lncRNA)-microRNA (miRNA) was constructed to reveal a new mechanism for the involvement of mutations in post-transcriptional regulation. We have also identified prognostic markers that are significantly associated with overall survival (OS) of PAAD patients and constructed a risk score model to identify patients’ survival risk. In summary, our study revealed the pathogenic mechanisms and prognostic markers of PAAD providing theoretical support for the development of precision medicine.
- 9 September 2021
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 12
Open AccessIntegrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) is one of the deadliest malignancies and mortality for PAAD have remained increasing under the conditions of substantial improvements in mortality for other major cancers. Although multiple of studies exists on PAAD, few studies have dissected the oncogenic mechanisms of PAAD based on genomic variation. In this study, we integrated somatic mutation data and gene expression profiles obtained by high-throughput sequencing to characterize the pathogenesis of PAAD. The mutation profile containing 182 samples with 25,470 somatic mutations was obtained from The Cancer Genome Atlas (TCGA). The mutation landscape was generated and somatic mutations in PAAD were found to have preference for mutation location. The combination of mutation matrix and gene expression profiles identified 31 driver genes that were closely associated with tumor cell invasion and apoptosis. Co-expression networks were constructed based on 461 genes significantly associated with driver genes and the hub gene FAM133A in the network was identified to be associated with tumor metastasis. Further, the cascade relationship of somatic mutation-Long non-coding RNA (lncRNA)-microRNA (miRNA) was constructed to reveal a new mechanism for the involvement of mutations in post-transcriptional regulation. We have also identified prognostic markers that are significantly associated with overall survival (OS) of PAAD patients and constructed a risk score model to identify patients’ survival risk. In summary, our study revealed the pathogenic mechanisms and prognostic markers of PAAD providing theoretical support for the development of precision medicine.
- 13 August 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (12) , 2118-2119
Acute Pancreatitis and Biliary Obstruction Induced by Ectopic Pancreas
- 13 August 2020
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 115 (12) , 2118-2119
Acute Pancreatitis and Biliary Obstruction Induced by Ectopic Pancreas
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB028
AB028. S028. Risk of the serous cystic neoplasms in pancreas results from no surgical intervention: a multi-center retrospective study
Background: Serous cystic neoplasms (SCN) of the pancreas are known as no malignant potential, so accurate diagnosis of SCN is significant for pancreatic cancer early detection and prevention as well as avoidance of unnecessary surgeries. However, the faults of preoperative diagnosis may highly increase the risk of carcinogenesis. Methods: A total of 99 patients with exactly preoperative diagnostic SCN and 678 patients with pathologically confirmed SCN were retrieved from sixteen institutions from January 1st, 2006 to December 31st, 2016. Analyses were conducted to evaluate the exact risks of SCN with no surgical intervention. Results: Of the 678 patients, 4 were pathologically verified as carcinogenesis, so the canceration rate was 0.6%, which was less than the risk of surgical interventions. However, among the 99 patients with exactly preoperative diagnostic SCN, 3 were verified as intraductal papillary mucinous neoplasms (IPMN), 9 as mucinous cystic neoplasms (MCN), 4 as solid pseudopapillary tumors (SPT). Thus the canceration rate through preoperative diagnosis had approximately elevated to 2.9%, which was obviously higher than the risks from surgeries. Conclusions: The preoperative diagnostic SCN still has the potential suitability for surgical resection. Therefore, one more precise diagnostic model should be investigated to improve the clinical practice.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB028
AB028. S028. Risk of the serous cystic neoplasms in pancreas results from no surgical intervention: a multi-center retrospective study
Background: Serous cystic neoplasms (SCN) of the pancreas are known as no malignant potential, so accurate diagnosis of SCN is significant for pancreatic cancer early detection and prevention as well as avoidance of unnecessary surgeries. However, the faults of preoperative diagnosis may highly increase the risk of carcinogenesis. Methods: A total of 99 patients with exactly preoperative diagnostic SCN and 678 patients with pathologically confirmed SCN were retrieved from sixteen institutions from January 1st, 2006 to December 31st, 2016. Analyses were conducted to evaluate the exact risks of SCN with no surgical intervention. Results: Of the 678 patients, 4 were pathologically verified as carcinogenesis, so the canceration rate was 0.6%, which was less than the risk of surgical interventions. However, among the 99 patients with exactly preoperative diagnostic SCN, 3 were verified as intraductal papillary mucinous neoplasms (IPMN), 9 as mucinous cystic neoplasms (MCN), 4 as solid pseudopapillary tumors (SPT). Thus the canceration rate through preoperative diagnosis had approximately elevated to 2.9%, which was obviously higher than the risks from surgeries. Conclusions: The preoperative diagnostic SCN still has the potential suitability for surgical resection. Therefore, one more precise diagnostic model should be investigated to improve the clinical practice.
- Open Access
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 25 (6)
Role of hyperlipidimia in pathogenesis of acute pancreatitis
高脂血症(hyperlipidemia, HL)与急性胰腺炎(acute pancreatitis, AP)之间的关系已成为胰腺疾病研究的热点. HL可能诱发AP, AP发生时也可能伴有脂类的代谢紊乱, 因此HL与AP可互为因果. HL包括高甘油三酯血症(hypertriglyceridemia, HTG)与高胆固醇血症(hypercholesterolemia, HTC)两类, 其中HTG作为AP的病因已经获得了国内外学者的公认, 而HTC是否可以引起AP的发生则尚未达成共识. 高脂血症性急性胰腺炎(hyperlipidemic acute pancreatitis, HLAP)的诊断除需满足AP的诊断外还要结合血脂水平而定, 但关于诊断HLAP的血脂水平的确定, 目前国内外仍未达成一致意见. 由于HLAP的诊断标准决定了诊治方案的选择并影响患者的预后, 因此统一的诊断标准的缺失使得HLAP的临床诊治工作仍面临着巨大的困难和挑战.
- 1 January 2017
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 25 (6)
Open AccessRole of hyperlipidimia in pathogenesis of acute pancreatitis
高脂血症(hyperlipidemia, HL)与急性胰腺炎(acute pancreatitis, AP)之间的关系已成为胰腺疾病研究的热点. HL可能诱发AP, AP发生时也可能伴有脂类的代谢紊乱, 因此HL与AP可互为因果. HL包括高甘油三酯血症(hypertriglyceridemia, HTG)与高胆固醇血症(hypercholesterolemia, HTC)两类, 其中HTG作为AP的病因已经获得了国内外学者的公认, 而HTC是否可以引起AP的发生则尚未达成共识. 高脂血症性急性胰腺炎(hyperlipidemic acute pancreatitis, HLAP)的诊断除需满足AP的诊断外还要结合血脂水平而定, 但关于诊断HLAP的血脂水平的确定, 目前国内外仍未达成一致意见. 由于HLAP的诊断标准决定了诊治方案的选择并影响患者的预后, 因此统一的诊断标准的缺失使得HLAP的临床诊治工作仍面临着巨大的困难和挑战.